By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on IWO, citing structural risks like 'zombie firm' solvency issues, high drawdowns, and liquidity fragility, outweighing recent outperformance and sector-specific opportunities.
Risk: Structural solvency risks due to high unprofitable firms and liquidity fragility across many holdings.
Opportunity: Tactical overweight for 6-12 months due to rotation from mega-tech and undervalued cyclical recovery plays.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
iShares Russell 2000 Growth ETF offers a higher expense ratio and a lower trailing-12-month dividend yield than State Street SPDR S&P 500 ETF Trust.
While iShares Russell 2000 Growth ETF outperformed over the last year, it has faced a significantly steeper maximum drawdown and lower five-year growth.
State Street SPDR S&P 500 ETF Trust concentrates on megacap technology while iShares Russell 2000 Growth ETF leans into healthcare and industrials.
iShares Russell 2000 Growth ETF (NYSEMKT:IWO) targets small-cap companies with rapid growth potential, whereas State Street SPDR S&P 500 ETF Trust (NYSEMKT:SPY) offers a diversified anchor of the largest U.S. corporations.
Investors may choose between the broad-market stability of the S&P 500 and the higher risk-reward potential of small-cap growth equities. The State Street SPDR S&P 500 ETF Trust serves as the global standard for large-cap domestic equity, while the iShares Russell 2000 Growth ETF filters smaller companies for aggressive expansion traits.
| Metric | SPY | IWO | |---|---|---| | Issuer | SPDR | iShares | | Expense ratio | 0.09% | 0.24% | | 1-yr return (as of May 7, 2026) | 31.90% | 43.20% | | Dividend yield | 1.00% | 0.40% | | Beta | 1.00 | 1.19 | | AUM | ~$753.9 billion | ~$14.3 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The iShares Russell 2000 Growth ETF is more expensive to hold with a 0.24% expense ratio compared to 0.09% for the SPDR trust. Additionally, the SPDR trust provides a higher payout, offering a 1.00% yield versus 0.40% for the iShares fund.
| Metric | SPY | IWO | |---|---|---| | Max drawdown (5 yr) | (24.50%) | (40.50%) | | Growth of $1,000 over 5 years (total return) | ~$1,856 | ~$1,268 |
The iShares Russell 2000 Growth ETF (IWO) focuses on small-cap growth, with primary sector allocations to Healthcare 25%, Technology 22%, and Industrials 21%. It holds 1,093 companies, and its largest positions include Bloom Energy (NYSE:BE) at 3.71%, Credo Technology Group Holding (NASDAQ:CRDO) at 1.79%, and Sterling Infrastructure (NASDAQ:STRL) at 1.38%. The fund was launched in 2000 and has a trailing-12-month dividend of $1.51 per share.
In contrast, the State Street SPDR S&P 500 ETF Trust (SPY) tracks large-cap benchmarks, tilting heavily toward Technology 34%, Financial Services 12%, and Communication Services 10%. Its top holdings include Nvidia (NASDAQ:NVDA) at 8.00%, Apple (NASDAQ:AAPL) at 6.68%, and Microsoft (NASDAQ:MSFT) at 4.87%. It manages 505 holdings, was launched in 1993, and paid $7.38 per share over the trailing 12 months.
For more guidance on ETF investing, check out the full guide at this link.
SPY and IWO occupy opposite ends of the U.S. equity universe, and putting them side by side makes the contrast vivid. SPY is the original U.S. ETF, tracking the S&P 500's 500 largest companies with nearly $685 billion in assets, making this a bedrock holding for millions of investors worldwide. IWO targets the riskiest, fastest-growing corner of the market: small-cap growth companies with high valuations, minimal profitability requirements, and significant room to either soar or stumble.
The sector profiles couldn't be more different. SPY leans heavily into megacap technology. IWO spreads across healthcare, industrials, and technology in roughly equal measure, with no single holding carrying meaningful weight and no company anywhere near the scale of an Apple or Nvidia.
SPY charges less than a third of what IWO does, and its long-term track record is hard to argue with. IWO suits investors who want to tilt aggressively toward small-cap growth and accept significantly more volatility in pursuit of higher long-term returns. For most portfolios, SPY is the foundation; IWO is the high-conviction satellite.
Before you buy stock in iShares Trust - iShares Russell 2000 Growth ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and iShares Trust - iShares Russell 2000 Growth ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 11, 2026. *
Sara Appino has positions in Apple and Nvidia. The Motley Fool has positions in and recommends Apple, Bloom Energy, Microsoft, Nvidia, and Sterling Infrastructure. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Small-cap growth's persistent underperformance over a 5-year horizon suggests that the index is structurally handicapped by low-quality, non-profitable firms that struggle to thrive in high-rate environments."
The article frames IWO as a 'high-conviction satellite' to SPY, but the 5-year performance data (1.26x vs 1.85x return) reveals a structural decay in the small-cap growth factor that investors cannot ignore. IWO’s 40.5% max drawdown isn't just volatility; it reflects the 'quality trap' where small-cap growth often lacks the balance sheet resilience to survive tightening credit cycles. While the 1-year outperformance (43.2% vs 31.9%) looks tempting, it is likely a mean-reversion trade rather than a secular shift. Unless we see a sustained decline in the cost of capital, IWO will continue to underperform on a risk-adjusted basis compared to the cash-flow-rich moats in SPY.
If the economy achieves a 'soft landing' with significant interest rate cuts, the valuation multiple expansion in small-cap healthcare and industrials could drastically outpace the already stretched P/E ratios of SPY’s megacap tech constituents.
"IWO's recent outperformance and cyclical sector exposure position it to outperform SPY in an impending rate-cut environment."
The article rightly flags SPY's superior 5-year total return (~86% vs IWO's 27%) and shallower drawdown, cementing it as the core holding, but glosses over why small-cap growth surged 43% vs SPY's 32% over the past year: a rotation from mega-tech amid peaking rates. IWO's healthcare (25%) and industrials (21%) tilt captures undervalued cyclical recovery plays like Bloom Energy (3.71% weight) in clean energy, absent SPY's Nvidia-heavy (8%) tech bet. With beta at 1.19, IWO amplifies upside in a Fed easing cycle, though its 0.24% expense erodes edge long-term. Tactical overweight merits for 6-12 months.
IWO's persistent 5-year underperformance and 40% max drawdown reflect small-growth's chronic valuation traps and profitability woes, which could worsen if recession hits before rate cuts materialize.
"The article conflates recent underperformance with structural unsuitability, ignoring that small-cap growth's 1-year lead and SPY's extreme tech concentration suggest the comparison is timing-dependent, not timeless."
This article presents a false choice dressed as diversification guidance. Yes, IWO underperformed SPY over five years (1.27x vs 1.86x), but that comparison is structurally misleading: we're comparing small-cap growth during a megacap tech supercycle. The article omits that IWO's 1-year outperformance (43.2% vs 31.9%) signals potential mean reversion—small caps often lead when rates fall or growth rotates. The 15-basis-point expense ratio gap (0.24% vs 0.09%) is real but immaterial over a decade. What's missing: IWO's valuation relative to SPY, sector cyclicality, and whether we're at peak tech concentration in SPY (34% in tech, three stocks at 19.5% combined).
If the Fed stays restrictive and recession risk rises, IWO's 40.5% max drawdown becomes a feature, not a bug—small-cap growth gets decimated first, and SPY's stability wins decisively for another 3-5 years.
"Over a multi-year horizon, SPY is likely to deliver more reliable risk-adjusted returns for most investors than IWO, because small-cap growth's premium is highly cyclical and vulnerable to drawdowns and liquidity risk."
Today's article frames IWO vs SPY as a stability-versus-growth choice, with last-year outperformance by IWO masking bigger pullbacks and an eye-watering five-year drawdown. Yet the piece glosses over real risk: small-cap growth is far more rate- and liquidity-sensitive, so a sustained macro shock or policy misstep could erase recent gains faster than SPY, even with AI tailwinds. The 0.15 percentage-point annual fee gap compounds over time, and dividend income differences matter in risk-off periods. Sector tilts (healthcare, industrials) imply higher exposure to reimbursement and capex cycles. In the end, a core–satellite approach may be wiser than a simple dichotomy.
Devil's advocate: If AI-driven productivity accelerates earnings in the small-cap universe and rates stabilize or fall, IWO's growth tilt could compound faster than SPY's megacap concentration suggests.
"IWO's high concentration of unprofitable firms creates a structural solvency risk that outweighs the potential for cyclical mean reversion."
Claude is right that comparing IWO to SPY during a megacap supercycle is flawed, but he ignores the 'zombie firm' risk. Roughly 40% of the Russell 2000 Growth index—IWO’s underlying benchmark—consists of companies with negative earnings. In a 'higher-for-longer' rate environment, these firms face existential refinancing cliffs that SPY’s profitable, cash-rich constituents simply do not. This isn't just cyclical rotation; it's a structural solvency risk that makes IWO a dangerous bet despite recent momentum.
"IWO's high private equity exposure introduces a liquidity risk from potential forced selling not faced by SPY."
Panel focuses on zombies and drawdowns, but misses IWO's acute exposure to private equity unwind: ~18% of Russell 2000 names have heavy PE ownership (per recent analyses), risking forced sales if LP commitments falter amid high rates. Gemini's unprofitable cohort overlaps heavily here, creating a solvency-liquidity double-whammy SPY entirely avoids.
"Correlation between unprofitability and PE ownership in R2K Growth is assumed, not demonstrated—critical before treating it as compounding risk."
Grok and Gemini are conflating two separate risks—unprofitability and PE exposure—without evidence they're correlated enough to compound. Yes, ~40% of R2K Growth is unprofitable, but that doesn't mean 18% PE-owned names are the same cohort. If they're mostly separate, the 'double-whammy' narrative collapses. Need actual overlap data before treating this as a unified solvency-liquidity crisis. The real question: what % of IWO's weight sits in both buckets simultaneously?
"In stress scenarios, macro liquidity risk in IWO dwarfs potential PE-backed zombie overlap as the core driver of drawdowns."
Grok's PE-unwind angle is plausible but hinges on overlap data we don't have; my bottom line is the bigger, more actionable risk is liquidity and refinancing fragility across a broad swath of IWO’s holdings, which can bite faster than a SPY beta drag in a stress shock. The 'double whammy' only matters if the overlap is material; otherwise it remains a tail risk. IWO's path will hinge on macro liquidity first.
The panel consensus is bearish on IWO, citing structural risks like 'zombie firm' solvency issues, high drawdowns, and liquidity fragility, outweighing recent outperformance and sector-specific opportunities.
Tactical overweight for 6-12 months due to rotation from mega-tech and undervalued cyclical recovery plays.
Structural solvency risks due to high unprofitable firms and liquidity fragility across many holdings.